Thrombospondin-1 (TSP-1) and Survivin (S) expression in non-Hogkin's lymphomas

Leukemia Research

Volumn 32, Issue 2, 2008, Pages 243-250

  Paydas, Semra ^a   Ergin, Melek ^a   Erdogan, Seyda ^a   Seydaoglu, Gulsah ^a   Yavuz, Sinan ^a   Disel, Umut ^a  

^a CUKUROVA UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

Agressivity; Lymphoma; Prognosis; Survivin; Thrombospondin 1

Indexed keywords

SURVIVIN; THROMBOSPONDIN 1;

ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; LYMPHOMA, NON-HODGKIN; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; THROMBOSPONDIN 1; TUMOR MARKERS, BIOLOGICAL;

EID: 38949212974     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.06.024     Document Type: Article

References (55)

1. Ambrosini G., Adida C., and Altieri D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3 (1997) 917-921
2. Tamm I., Schriever F., and Dörken B. Apoptosis: implications of basic research for clinical oncology. Lancet Oncol 2 (2001) 33-42
3. Son B.H., Choi J.S., and Lee J.H. Prognostic values of KAI1 and survivin expression in an infiltrating ductal carcinoma of the breast. Pathology 37 2 (2005) 131-136
4. Wagner M., Schmelz K., Wuchter C., Ludwig W.D., Dörken B., and Tamm I. In vivo expression of survivin and its splice variant survivin-2B: impact on clinical outcome in acute myeloid leukemia. Int J Cancer 119 (2006) 1291-1297
5. Nakagawa Y., Hasegawa M., Kurata M., Yamamoto K., Abe S., Inoue M., et al. Expression of IAP-family proteins in adult acute mixed lineage leukemia. Am J Hematol 78 (2005) 173-180
6. Watanki-Miyauchi R., Kojima Y., Tsurami H., Hara T., Goto N., Kasahara S., et al. Expression of antigen detected by a novel monoclonal antibody, T332, is associated with outcome of diffuse large B-cell lymphoma and its subtypes. Pathol Int 55 (2005) 324-330
7. Tracey L., Perez-Rosado A., Artiga M.J., Camacho F., Rodriguez A., Martinez N., et al. Expression of the NF-k B targets BCL2 and BIRC5/survivin characterizes small B cell and aggressive B-cell lymphomas, respectively. J Pathol 206 (2005) 123-134
8. Carter B.Z., Mak D.H., Schober W.D., Cabreira-Hansen M., Beran M., and McQueen T. Regulation of survivin expression through BCR-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells. Blood 107 (2006) 1555-1563
9. Schlette E.J., Medeiros L.J., Goy A., Lai R., and Rassidakis G.Z. Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. J Clin Oncol 22 (2004) 1682-1688
10. Martinez A., Bellosillo B., Bosch F., Ferrer A., Marce S., Villamor N., et al. Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival. Am J Pathol 164 (2004) 501-510
11. Adida C., Haioun C., Gaulard P., Lepage E., Morel P., Briere J., et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 96 (2000) 1921-1925
12. Altieri D.C. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3 (2003) 46-54
13. Kamihira S., Yamada Y., Hirakata Y., Tomanaga M., Sugahara K., Hayashi T., et al. Aberrant expression of caspase cascade regulatory genes in adult T-cell leukemia: survivin is an important determinant for prognosis. Br J Haematol 114 (2001) 63-69
14. Clezardin P., Lawler J., Amiral J., Quentin G., and Delmas P. Identification of cell adhesive sites in the N-terminal domain of thrombospondin-1. Biochem J 321 (1997) 819-827
15. Lawler J., Ferro P., and Duquette M. Expression and mutagenesis of thrombospondin. Biochemistry 31 (1992) 1173-1180
16. Merle B., Malaval L., Lawler J., Delmas P., and Clezardin P. Decorin inhibits cell attachment to thrombospondin-1 by binding to a KKTR-dependent cell adhesive site present within the N-terminal domain of thrombospondin-1. J Biochem 67 (1997) 75-83
17. Volpert O.V., Zaichuk T., Zhou W., Reiher F., Ferguson T.A., Stuart P.M., et al. Inducer stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med 5 (2002) 349-357
18. Armstrong L.C., and Bornstein P. Thrombospondin-1 and 2 function as inhibitors of angiogenesis. Matrix Biol 22 (2006) 63-71
19. Iuela-Aispe M.L., Luque A., and Lee N. Thrombospondin modulates and angiogenesis. Int J Biochem Cell Biol 35 (2004) 1070-1076
20. Lawler J., and Detmer M. Tumor progression: the effects of thrombospondin-1 and 2. Int J Biochem Cell Biol 36 (2004) 1036-1045
21. Lawler J., and Detmar M. Tmor progression: the effects of thrombospondin-1 and 2. Int J Biochem Cell Biol 36 (2004) 1038-1045
22. Desoize B. Stromal reaction and tumor growth. Crit Rev Oncol Hematol 49 (2004) 173-176
23. Li F., Yang J., Ramnath N., Javle M.M., and Tan D. Nuclear or cytoplasmic expression of survivin: what is the significance?. Int J Cancer 114 (2005) 509-512
24. Xie D., Zeng Y.X., Wang H.J., Wen J.M., Tao Y., Sham J.S.T., et al. Expression of cytoplasmic and nuclear survivin in primary and secondary human glioblastoma. Br J Cancer 94 (2006) 108-114
25. Sarela A.I., Macadam R.C., Farnery S.M., Markham A.F., and Guilou P.J. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 46 (2000) 645-650
26. Tamm I., Richter S., Oltersdorf D., Creutzig U., Harbott J., Scholz F., et al. High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia. Clin Cancer Res 10 (2004) 3737-3744
27. Adida C., Recher C., Raffoux E., Daniel M.T., Taksin A.L., Rousselot P., et al. Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br J Haematol 111 (2000) 196-203
28. Nakayama K., and Kamihira S. Survivin an important determinant for prognosis in adult T-cell leukemia: a novel biomarker in practical hemato-oncology. Leuk Lymphoma 43 (2002) 2249-2255
29. Kamihira S., Yamada Y., Hirakata Y., Tomonaga M., Sugahara K., Hayashi T., et al. Aberrant expression of cascade regulatory genes in adult T-cell leukemia: survivin is an important determinant for prognosis. Br J Haematol 114 (2001) 63-69
30. Che X.F., Zheng C.L., Owatari S., Mutch M., Gotando T., Jeung H.C., et al. Overexpression of survivin in primary ATL cells and odium arsenite induces apoptosis by down-regulating survivin expression in ATL cell lines. Blood 107 (2006) 4880-4887
31. Sugahara K., Uemura A., Harasawa H., Nagai H., Hirakata Y., Tomonaga M., et al. Clinical relevance of survivin as a biomarker in neoplasms, especially in adult T-cell leukemias and acute leukemias. Int J Hematol 80 (2004) 52-58
32. Nakagawa Y., Yamaguchi S., Hasegawa M., Nemoto T., Inoue M., Suzuki K., et al. Differential expression of survivin in bone marrow cells from patients with acute lymphocytic leukemia and chronic lymphocytic leukemia. Leuk Res 28 (2004) 487-494
33. Conte E., Stagno F., Guglielmo P., Scuto A., Consoli C., and Messina A. Survivin expression in chronic myeloid leukemia. Cancer Lett 225 (2005) 105-110
34. Invernizzi R., Travaglino E., Benatti C., Malcovati L., Porta M.D., Cazzola M., et al. Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia. Eur J Haematol 76 (2006) 494-501
35. Hui D., Satkunam N., Al Kaptan M., Reiman T., and Lai R. Pathway-specific apoptotic gene expression profiling in chronic lymphocytic leukemia and follicular lymphoma. Mod Pathol 19 (2006) 1192-1202
36. Schlette E.J., Mederios L.J., Goy A., Lai R., and Rassidakis G.Z. Survivin expression predicts poorer prognosis in anaplastic large cell lymphoma. J Clin Oncol 22 (2004) 1682-1688
37. Xiang X.J., and He Y.J. Clinical significance of survivin and caspase-3 expression in diffuse large B-cell lymphoma. Zhonghua Zhong Liu Za Zhi 28 (2006) 298-301
38. Li J.F., Li G.D., Liu W.P., Wang Y., Cheng J.R., Chen Y., et al. Expression of anaplastic lymphoma kinase and survivin proteins in anaplastic large cell lymphoma and its significance. Zhonghua Bing Li Xue Za Zhi 35 (2006) 213-217
39. Xiang X.J., He Y.J., Li Y.H., Huang H., and Xu F. Clinical significance of survivin expression in peripheral T-cell lymphoma. Ai Zheng 25 (2006) 758-761
40. Zuo X.L., Zhou X., Meng J., Zhang K.J., Liu X.H., and Yang H.Q. A study on the expression of myeloid cell leukemia 1 proteins and survivin and their relation with B cell apoptosis in non-Hodgkin's lymphoma. Zhonghua Nei Ke Za Zhi 45 (2006) 133-135
41. Martinez A., Bellesilo B., Bosch F., Ferrer A., Marce S., Villamor N., et al. Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival. Am J Pathol 164 (2004) 501-510
42. Ambrosini G., Adida C., Sirugo G., and Altieri D.C. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem 273 (1998) 11177-11182
43. Siegel S., Wagner A., Schmitz N., and Zeis M. Induction of antitumor immunity using survivin peptide-pulsed dendritic cells in a murine lymphoma model. Br J Haematol 122 (2003) 911-914
44. Zeis M., Siegel S., Wagner A., Schmitz M., Marget M., Kuhl-Burmeister R., et al. Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells. J Immunol 170 (2003) 5391-5397
45. Ansell S.M., Arendt B.K., Grote D.M., Jelinek D.F., Novak A.J., Welik L.E., et al. Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma. Leukemia 18 (2004) 616-623
46. Sid B., Sartelet H., Bellon G., Btaouri H.E., Rath G., Delorme N., et al. Thrombospondin 1: a multifunctional protein implicated in the regulation of tumor growth. Crit Rev Oncol Hematol 49 (2004) 245-258
47. Adams J.C. Thrombospondins: multifunctional regulators of cell interactions. Ann Rev Cell Dev Biol 17 (2001) 25-51
48. Bocci G., Francia G., Man S., Lawler J., and Kerbel R.S. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. PNAS 100 (2003) 12917-12922
49. Bellon G., Martiny L., and Robinet A. Matrix metalloproteinases and matrikines in angiogenesis. Crit Rev Oncol Hematol 49 (2004) 203-220
50. Gietema J.A., Hoekstra R., de Vos F.Y.F.L., Uges D.R.A., der Gaast A., Greon H.J.M., et al. A phase I study assessing the safety of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors. Ann Oncol 17 (2006) 1320-1327
51. Sund M, Hamano Y, Sugimoto H, Sudhakar A, Soubasakos M, Yerramalla U, et al. Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor.
52. Scarpino S., Di Napoli A., Taraboletti G., Cancrini A., and Ruco L.P. Hepatocyte growth factor (HGF) downregulates thrombospondin-1 (TSP-1) expression in thyroid papillary carcinoma cells. J Pathol 205 (2005) 50-56
53. Yee K.O., Streit M., Hawighorst T., Detmer M., and Lawler J. Expression of the type-1 repeats of thrombospondin-1 inhibits tumor growth through activation of transforming growth factor-β. Am J Pathol 165 (2004) 541-552
54. Albo D., and Tuszynski G.P. Thrombospondin 1 up regulates tumor cell invasion through the urokinase plasminogen activator receptor in head and neck cancer cells. J Surg Res 120 (2004) 21-26
55. Linderholm B., Karlsson E., Klaar S., Lindahl T., Borg A.L., Elmberger G., et al. Thrombospondin-1 expression in relation to p53 status and VEGF expression in human breast cancers. Eur J Cancer 40 (2004) 2417-2423